Your search history is turned on.
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario, Quebec
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Nicholas Sosiak, the Chief Financial Officer of Cannara Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Cannara Biotech Inc. (the issuer) for the interim period ended February...
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Zohar Krivorot, the Chief Executive Officer of Cannara Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Cannara Biotech Inc. (the issuer) for the interim period ended February ...
Microsoft Word - Cannara - Q2 2024 MD&A Final - Mailing MADE WITH LOVE For the three and six-month periods ended February 29, 2024 Apri l 29 , 2024 TSXV: LOVE OTCQB: LOVFF FRA: 8CB0 Q u e b e c G r o w n P r e m i u m G r a d e C a n n a b i s C A N N A R A B I O T E C H I N C . CANNARA BIOTECH INC. Management Discussion ...
CANNARA BIOTECH INC. Condensed Interim Consolidated Financial Statements For the three and six-month periods ended February 29, 2024 and February 28, 2023 (Unaudited) CANNARA BIOTECH INC. Table of Contents (Unaudited) Page Financial Statements of C...
Cannara Biotech publie ses rsultats financiers pour le deuxime trimestre de 2024 Les revenus nets ont augment pour aeindre 19,7 millions de dollars au deuxime trimestre de 2024, contre 13,0 millions de dollars au deuxime trimestre 2023, soit une augmentaon de 51,0 %. Le bnfice brut, avant ajustement de la juste valeur, a augment pour a...
Cannara Biotech Reports Q2 2024 Financial Results Net revenue, increased to $19.7 million in Q2 2024 from $13.0 million in Q2 2023, a 51.0% increase. Gross profit, before fair value adjustments, increased to $7.1 million in Q2 2024 from $4.0 million in Q2 2023, a 77.2% increase. Delivered a twelh consecuve quarter of posive Adjusted EBITDA1 o...
Date: January 30, 2024 Jurisdictions: Alberta, British Columbia, Ontario, Quebec
Communiqu Cannara Biotech annonce des rsultats records pour le premier trimestre de 2024 : Croissance robuste continue et expansion du march Des revenus nets records de 19,5 millions de dollars au premier trimestre, soit une augmentation de 89 % par rapport aux revenus nets de 10,3 millio...
Microsoft Word - LOVE q1 2024 pr final draft_v4 - Copy Press Release Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion Record Q1 net revenues of $19.5 million, representing an 89% increase compared to the $10.3 million of net revenues generated in Q1 2023 Q1 operating income of $3.4 million, repr...
Date: January 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario, Quebec
Microsoft Word - CFO certification - Q1 2024 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Nicholas Sosiak, the Chief Financial Officer of Cannara Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Cannara Biotech Inc....
Microsoft Word - CEO certification - Q1 2024 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Zohar Krivorot, the Chief Executive Officer of Cannara Biotech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Cannara Biotech Inc. ...